CN110730781B - Gpr6的四氢吡啶并吡嗪调节剂 - Google Patents

Gpr6的四氢吡啶并吡嗪调节剂 Download PDF

Info

Publication number
CN110730781B
CN110730781B CN201880038831.4A CN201880038831A CN110730781B CN 110730781 B CN110730781 B CN 110730781B CN 201880038831 A CN201880038831 A CN 201880038831A CN 110730781 B CN110730781 B CN 110730781B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
certain embodiments
dose
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880038831.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110730781A (zh
Inventor
J·W·布朗
S·希驰库克
M·霍普金斯
菊地正太
H·蒙恩斯城
H·雷查德
K·施莱克尔
孙会凯
T·麦克林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN110730781A publication Critical patent/CN110730781A/zh
Application granted granted Critical
Publication of CN110730781B publication Critical patent/CN110730781B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880038831.4A 2017-06-15 2018-06-15 Gpr6的四氢吡啶并吡嗪调节剂 Active CN110730781B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762520430P 2017-06-15 2017-06-15
US62/520,430 2017-06-15
US201762591247P 2017-11-28 2017-11-28
US62/591,247 2017-11-28
US201862649856P 2018-03-29 2018-03-29
US62/649,856 2018-03-29
US201862672261P 2018-05-16 2018-05-16
US62/672,261 2018-05-16
PCT/US2018/037687 WO2018232202A1 (en) 2017-06-15 2018-06-15 Tetrahydropyridopyrazine modulators of gpr6

Publications (2)

Publication Number Publication Date
CN110730781A CN110730781A (zh) 2020-01-24
CN110730781B true CN110730781B (zh) 2023-05-05

Family

ID=64656005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880038831.4A Active CN110730781B (zh) 2017-06-15 2018-06-15 Gpr6的四氢吡啶并吡嗪调节剂

Country Status (25)

Country Link
US (1) US10406157B2 (enExample)
EP (1) EP3638673B9 (enExample)
JP (2) JP7460369B2 (enExample)
KR (1) KR102802861B1 (enExample)
CN (1) CN110730781B (enExample)
AU (1) AU2018285677B2 (enExample)
CA (1) CA3067032A1 (enExample)
CO (1) CO2019015086A2 (enExample)
DK (1) DK3638673T3 (enExample)
ES (1) ES2988680T3 (enExample)
FI (1) FI3638673T3 (enExample)
HR (1) HRP20241231T1 (enExample)
HU (1) HUE068346T2 (enExample)
IL (1) IL271332B2 (enExample)
JO (1) JOP20180057A1 (enExample)
LT (1) LT3638673T (enExample)
MX (1) MX2019014940A (enExample)
PH (1) PH12019502792A1 (enExample)
PL (1) PL3638673T3 (enExample)
PT (1) PT3638673T (enExample)
RS (1) RS66018B1 (enExample)
SG (1) SG11201912149WA (enExample)
SI (1) SI3638673T1 (enExample)
TW (1) TWI775874B (enExample)
WO (1) WO2018232202A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026067262A1 (zh) * 2024-09-26 2026-04-02 四川科伦药物研究院有限公司 并环化合物、包含其的药物组合物及其用途和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229557B2 (en) * 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
WO2015123505A1 (en) * 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
CN105829309A (zh) * 2013-12-20 2016-08-03 武田药品工业株式会社 Gpr6的四氢吡啶并吡嗪调节剂
CN106103421A (zh) * 2014-02-14 2016-11-09 武田药品工业株式会社 Gpr6的吡嗪调节剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2011005636A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229557B2 (en) * 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
CN105829309A (zh) * 2013-12-20 2016-08-03 武田药品工业株式会社 Gpr6的四氢吡啶并吡嗪调节剂
WO2015123505A1 (en) * 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
CN106103421A (zh) * 2014-02-14 2016-11-09 武田药品工业株式会社 Gpr6的吡嗪调节剂

Also Published As

Publication number Publication date
EP3638673B9 (en) 2024-11-20
CN110730781A (zh) 2020-01-24
PT3638673T (pt) 2024-10-07
IL271332B2 (en) 2023-02-01
AU2018285677A1 (en) 2019-12-19
FI3638673T3 (fi) 2024-09-13
PH12019502792A1 (en) 2020-09-14
KR20200014796A (ko) 2020-02-11
AU2018285677B2 (en) 2022-07-14
TWI775874B (zh) 2022-09-01
HUE068346T2 (hu) 2024-12-28
JP2020523287A (ja) 2020-08-06
JP7497400B2 (ja) 2024-06-10
PL3638673T3 (pl) 2024-11-18
EP3638673B1 (en) 2024-07-17
SG11201912149WA (en) 2020-01-30
US20180360831A1 (en) 2018-12-20
US10406157B2 (en) 2019-09-10
KR102802861B1 (ko) 2025-04-30
LT3638673T (lt) 2024-09-10
WO2018232202A1 (en) 2018-12-20
CA3067032A1 (en) 2018-12-20
EP3638673A4 (en) 2021-03-24
RU2019144408A (ru) 2021-07-15
IL271332B (en) 2022-10-01
TW201906844A (zh) 2019-02-16
IL271332A (en) 2020-01-30
HRP20241231T1 (hr) 2024-12-20
JP7460369B2 (ja) 2024-04-02
MX2019014940A (es) 2020-02-19
SI3638673T1 (sl) 2025-01-31
DK3638673T3 (da) 2024-09-16
NZ759708A (en) 2024-04-26
EP3638673A1 (en) 2020-04-22
JP2022188199A (ja) 2022-12-20
ES2988680T3 (es) 2024-11-21
RS66018B1 (sr) 2024-11-29
CO2019015086A2 (es) 2020-04-13
RU2019144408A3 (enExample) 2021-09-07
BR112019026430A2 (pt) 2020-07-14
JOP20180057A1 (ar) 2019-01-30

Similar Documents

Publication Publication Date Title
TWI920639B (zh) Shp2之八氫環戊烷并[c]吡咯別構抑制劑
ES2927954T3 (es) Compuestos 2,5-dioxo-azolina N-sustituidos para la utilización en el tratamiento del cáncer
JP7398156B2 (ja) Ｓｔａｔ３二機能性リン酸化部位を標的とするトリアロマティック化合物のクラスおよびその応用
CA3092450A1 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
JP2022526295A (ja) キノリンおよびキナゾリン化合物およびその使用方法
JP2012519704A (ja) 認知増強用化合物及び組成物、製造法、並びに治療法
CA3119912A1 (en) A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
CA3255222A1 (en) N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
CA3178447A1 (en) N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as sstr4 agonists
JP7497400B2 (ja) Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター
RU2818783C2 (ru) Тетрагидропиридопиразиновые модуляторы gpr6
HK40022760A (en) Tetrahydropyridopyrazine modulators of gpr6
HK40022760B (en) Tetrahydropyridopyrazine modulators of gpr6
CN106336387A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
BR112019026430B1 (pt) Composto de tetrahidropiridopirazina ou seus sais aceitáveis, composição comprendendo o mesmo, combinação, e seu uso no tratamento de doença relacionada ao gpr6
TW202530182A (zh) Ｎ—（１—（胺基甲基）環丙基）（芳基或雜芳基）甲醯胺衍生物
HK40023760B (en) Sulfonamide compounds and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant